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Abstract
Dermatofibrosarcoma protuberans (DFSP) is a very rare soft tissue sarcoma. DFSP often reveals a specific chromosome
translocation, t(17;22)(q22;q13), which results in the fusion of collagen 1 alpha 1 (COL1A1) gene and platelet-derived growth
factor-B (PDGFB) gene. The COL1A1-PDGFB fusion protein activates the PDGFB receptor and resultant constitutive activation
of PDGFR receptor is essential in the pathogenesis of DFSP. Thus, blocking PDGFR receptor activation with imatinib has
shown promising activity in the treatment of advanced and metastatic DFSP. Despite the success with targeted agents in
cancers, acquired drug resistance eventually occurs. Here, we tried to identify potential drug resistance mechanisms against
imatinib in a 46-year old female with DFSP who initially responded well to imatinib but suffered rapid disease progression.
We performed whole-genome sequencing of both pre-treatment and post-treatment tumor tissue to identify the
mutational events associated with imatinib resistance. No significant copy number alterations, insertion, and deletions were
identified during imatinib treatment. Of note, we identified newly emerged 8 non-synonymous somatic mutations of the
genes (ACAP2, CARD10, KIAA0556, PAAQR7, PPP1R39, SAFB2, STARD9, and ZFYVE9) in the imatinib-resistant tumor tissue. This
study revealed diverse possible candidate mechanisms by which imatinib resistance to PDGFRB inhibition may arise in DFSP,
and highlights the usefulness of whole-genome sequencing in identifying drug resistance mechanisms and in pursuing
genome-directed, personalized anti-cancer therapy.
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Introduction
Dermatofibrosarcoma protuberans (DFSP) is a very rare tumor,
with an incidence of only 0.8 to 4.5 cases per million persons per
year in the United States [1–3]. The standard treatment for DFSP
is local surgical excision with wide resection margins [4,5].
However, local recurrence rates are high because of its infiltrative
growth, and there is a small but definite risk (1% to 4%) of distant
metastasis [4,6].
Cytogenetic analysis of DFSP often reveals a specific chromo-
some translocation, t(17;22)(q22;q13), which results in the fusion of
collagen 1 alpha 1 (COL1A1) gene and platelet-derived growth
factor-B (PDGFB) gene [7–10]. The resulting COL1A1-PDGFB
fusion protein eventually activates the PDGFB receptor
(PDGFRB), which acts as a protein tyrosine kinase and a potent
growth factor [11,12]. This discovery prompted further studies on
the use of PDGFRB tyrosine kinase inhibitors, such as imatinib,
for the treatment of advanced and metastatic DFSP. Imatinib
showed good activity against DFSP in preclinical studies and in a
series of clinical trials each involving only a small numbers of
patients because of the rarity of the disease [11–17]. However, a
recent pooled analysis of two phase II trials also reported
promising clinical activity of imatinib with an objective response
rate approaching 50% and a 1-year overall survival (OS) rate of
87.5% [18]. Beyond this however, there is no established salvage
treatment after failure of imatinib for DFSP, and the acquisition of
imatinib resistance has never been investigated by systematic
approaches. Here, we described the results of a whole genome
sequencing study on both primary DFSP tumor and tumor cells
taken at the time of disease progression after imatinib therapy had
failed. We were able to identify a number of genetic changes
associated with imatinib resistance.
Materials and Methods
Ethics Statement
The protocol was approved by the Samsung Medical Center
Institutional Review Board (SMC IRB), and the study was
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conducted in accordance with the 1996 Declaration of Helsinki.
Written informed consent was obtained from the patient.
Sample Preparation and Whole Genome Amplification
Tumor specimens were collected from a paraspinal mass before
and after imatinib treatment by means of computed tomography
(CT)-guided biopsy. DNA was extracted from both tumor samples
using a commercially available kit. The DNA yield from the post-
imatinib tumor was less than 100 ng, and in order to obtain
sufficient DNA for library construction, whole genome amplifica-
tion was performed on approximately 20 ng of this DNA using the
REPLI-g Mini Kit (Qiagen) according to the manufacturer’s
instructions. A 2.5 mL aliquot of template DNA was denatured at
room temperature for 3 min and was then neutralized using an
acidic buffer provided by the manufacturer. The denatured DNA
was mixed with Q29 DNA polymerase and reaction buffer to a
total volume of 50 mL and incubated at 30uC for 16 hrs in a
GeneAmp PCR System 9700 thermal cycler (Life Technologies).
After amplification, the DNA polymerase was inactivated by
heating the sample for 3 min at 65uC. In order to increase the
yield, three independent reactions were performed and the
amplified products were pooled together after whole genome
amplification. DNA integrity was evaluated by running the
samples on 2% agarose gel electrophoresis. The total yield of
DNA was 6.72 mg.
Library Construction
Libraries of qualified genomic DNA were prepared for paired-
end analysis on the Illumina Cluster Station and Illumina HiSeq
2000. To minimize the likelihood of systematic bias in sampling,
three paired-end libraries with an insert size of 500 bp were
prepared for all samples in this study. The qualified genomic
DNA was fragmented into lengths of approximately 500 bp
using Covaris (E210). The double-stranded DNA fragments
contained 39 or 59 overhangs, which were converted into blunt
ends using T4 DNA polymerase and Klenow enzyme. Adeno-
sine was added to the 39 end of the blunt phosphorylated DNA
fragments, and adapters were then ligated to both ends. The
correctly ligated products were separated by agarose gel
electrophoresis and then purified using the QIAquick gel
extraction kit. The purpose of this step is to remove residual
free and self-ligated adaptors and to select correctly sized
templates for cluster generation. DNA fragments with adapter
molecules on both ends were selected and amplified. Polymerase
chain reaction (PCR) was performed with the two primers that
annealed to the ends of the adapters. The number of PCR cycles
was minimized to avoid skewing the representation of the
library, and the PCR products were checked and purified by
agarose gel electrophoresis. They were then used in the library
test step and the average fragment size and molar concentration
of the library were determined by using an Agilent 2100
Bioanalyzer and an ABI Real-Time PCR System (StepOne-
PlusTM), respectively.
Sequencing
The sequencing method was based on that of the Illumina
HiSeq2000 platform, and we used a fully automated protocol
whereby clustered template DNA was sequenced using four-color
DNA Sequencing-By-Synthesis technology with reversible termi-
nators and removable fluorescence. Raw image files were
processed by the Illumina pipeline for base-calling using the
default parameters, and the sequences for each individual were
generated as 90 bp paired-end reads. Each library was subjected
to 7 lanes, resulting in an at least 50-fold haploid coverage for
each sample. The sequencing data were subjected to a strict
quality control (QC) test before bioinformatics analysis. The raw
whole genome sequence data has been uploaded at the NCBI
Sequence Read Achieve (SRA) under the accession number
SRA075959.
Pipeline of Bioinformatics Analysis
The bioinformatics analysis began with the sequencing data
(raw data) that was generated from HiSeq2000. In the first step,
the adapter sequence in the raw data was removed, and low
quality reads that had too many unreadable or low quality bases
were discarded, producing ‘‘clean data’’. For the second step, a
Burrows-Wheeler Aligner (BWA) was used for alignment. BWA can
generate results in a BAM file format, which is a requirement for a
number of the subsequent processes, such as fixing the mate
information of the alignment, adding read group information, and
removing duplicate reads caused by PCR. After these processes,
the final BAM files used for the variant calling were prepared.
Single nucleotide polymorphism (SNP) analysis was performed
using SAMtools, and potential somatic single nucleotide variants
(SNVs) were predicted using Varscan (v2.2.5) [19]. We then used
our filter pipeline to identify somatic mutations, with the following
major criteria: (1) The adjacent somatic mutation distance should
be equal to or greater than 10 bp; (2) the mapping quality score
should not be significantly lower than 30 (Wilcoxon test, p,0.20);
(3) the base quality score should not be significantly lower than 20
(Wilcoxon test, p,0.05); (4) there should be a significant allele
frequency change between the tumor and the matched adjacent
normal tissue (Fisher’s exact test p,0.05); (5) the mutation should
not be in gap-aligned reads (less than 10 gap flags within a 20 bp
flank region); (6) mutations should not be significantly enriched
within 5 bp of the 59 or 39 ends of the read (Wilcoxon test,
p,0.05); and (7) mutations should not be in a simple repeat region
(i.e., the repeat events should be less than 6). Small insertion/
deletions (InDels) were detected using SAMtools, and structure
variants (SVs) and copy number variants (CNVs) were identified
using BreakDancer and a method we devised by ourselves based on
the Segseq algorithm [20], respectively. ANNOVAR was used to
annotate confident variant results. The final variant scan could
then be used in the downstream advanced analysis pipeline. QC
was applied throughout the entire process to obtain clean data,
alignment and called variants.
Genomic Profiling
We aligned sequencing reads to the reference genome sequence
using the BWA software, and these were then mapped using the
human genome build 37 (Hg19) as the reference genome. The
whole genome size of Hg19 is 3,137,161,264 bp, whereas its
effective size is 2,861,327,131 bp (excluding unreadable bases,
random regions, hap regions, chromosome Un, and chromosome
M in the reference), and is available at http://hgdownload.cse.
ucsc.edu/goldenPath/hg19/bigZips/. We used Picard software
(http://picard.sourceforge.net/) to mark duplication, which is
redundant information produced by PCR. After this, the
alignment results were merged to give a single BAM format file,
which is the compressed binary form of a Sequence Alignment/
Map (SAM) file by sample.
The BAM file can be used to visualize aligned reads using
SAMtools or other genome browsers, such as the Integrative Genomics
Viewer (IGV). For genome re-sequencing, the per-base sequencing
depth should theoretically have a Poisson distribution. However,
due to the differences between each sample and the reference, the
actual distribution might show divergence from the theoretical
value. Therefore, this analysis can be used to identify differences
Imatinib Resistance in DFSP
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between the genome of the sample and the reference. Depth was
calculated for each base from the aligned reads. Reads with
multiple equal best placements were randomly assigned to one
best-hit location. Sequencing depths exhibited a Poisson-like
distribution with average depths of 69.706, 66.556 and 68.266,
for the blood DNA, the imatinib-sensitive (pre-treatment) tumor,
and the imatinib-resistant (post-treatment) tumor, respectively.
Results
Case History
A 46-year old woman presented at Samsung Medical Center
with a paravertebral soft-tissue mass at the level of L3–4. She had
been diagnosed four years ago with DFSP that had formed a
subcutaneous lesion on the left thigh that was subsequently
surgically resected. Three years later, the disease recurred in a
paraspinal space at the level of L5–S1, and she had received
further surgery followed by postoperative radiotherapy to the
surgical bed. At recurrence, she suffered from mild lower back
pain and a tingling sensation in the left posterior thigh and the
lateral calf area. Magnetic resonance imaging (MRI) of the lumbar
spine revealed a 4-cm, lobulated, enhancing soft-tissue mass in the
left paravertebral muscle at the level of L3–4 (Fig. 1A; lumbar
spine MRI, left panel). A routine chest radiograph showed a
nodular lesion in the right upper lung (RUL) zone and a
subsequent chest computed tomography (CT) scan showed
multiple lung nodules with the largest one located in the RUL
zone (Fig. 1A; chest CT, right panel). Core biopsy of left back mass
confirmed the presence of metastatic DFSP (Fig. 2), and
subsequently, a unique translocation involving chromosomes 17
and 22 was found in the tumor cells (data not shown). Hence, the
patient was diagnosed with recurrent DFSP with multiple lung
metastases that were not amenable to surgical resection.
Accordingly, we started imatinib therapy at a dose of 400 mg
per day, every day. After 4 months of this treatment, follow-up
spine MRI (Fig. 1B; lumbar spine MRI, left panel) and chest CT
(Fig. 1B; chest CT, right panel) confirmed a partial response.
After 6 months of imatinib treatment, however, the lung
metastases and paraspinal mass were found increased in size,
suggesting that the tumors had developed resistance to imatinib.
At this point, the dose of imatinib was increased to 800 mg per
day, every day. After a further 3 months treatment with this
higher dose, the paraspinal mass was found to have grown larger
with direct invasion to the L5–S1 neural foramen (Fig. 1C;
lumbar spine MRI, left panel). A chest CT scan also showed
progressive disease with increased RUL nodule size (Fig. 1C;
chest CT, right panel). At this time, after a thorough discussion
with the patient and obtaining written informed consent (using
the form approved by the SMC Institutional Review Board), we
re-biopsied the imatinib-resistant paraspinal mass under CT
guidance. The tumor content of the biopsy was found to be over
80% based on pathologic examination by pathologist YRC. DNA
was extracted from both this specimen and from the original
paraspinal mass, which was sensitive to imatinib, and whole
genome sequencing was performed. At this time, the patient was
treated with doxorubicin-ifosfamide chemotherapy, sunitinib, and
pazopanib, sequentially. The patient did not respond to any of
these subsequent regimens and had a rapidly deteriorating
clinical course mainly due to progression to leptomeningeal
metastases spread from the paraspinal mass (Fig. 1D). Unfortu-
nately, the patient died of disease progression.
Variation Detection and Annotation
1) SNP. We used SAMtools to detect SNPs, and ANNOVAR for
their annotation and classification. A statistical analysis of the
SNP distribution (see supplementary Table 1) was
performed to evaluate the number of SNPs located in
different gene regions.
2) SNV. Previously, Varscan software has mainly been used to
identify tumor-specific somatic substitutions by comparing
tumor and normal tissue in pairs. Here, we used Varscan to
identify tumor-specific SNVs by simultaneously comparing
read counts, base quality, and allele frequency between the
blood/normal tissue (B/N) and the tumor tissue (T) genomes.
After identifying the SNVs, we also used ANNOVAR for
annotation and classification. A statistical analysis of the SNV
distribution (see supplementary Table 2) was generated to
evaluate the number of SNVs located in different gene
regions.
By analyzing the somatic mutation spectrum of each sample,
we found that for the normal versus DFSP genomes,
G:C.T:A accounted for the majority of all detected SNVs.
The x-axis denotes the number of SNV mutations, and the y-
Figure 1. A 46-year old women with DFSP at paravertebral site at the level of L3–4 and RUL zone of chest. Lumbar spine MRI and chest
CT were taken. A, before initiation of treatment with imatinib. B, after 4 months treatment with imatinib. C, after further 2 months treatment with
imatinib and 3 months treatment with higher dose imatinib. D, at the time of disease progression with leptomeningeal metastasis.
doi:10.1371/journal.pone.0069752.g001
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axis lists each mutation (see supplementary Fig. 1). We
also analyzed the SNVs in coding sequences and splice
regions, and found that, in normal versus tumor genomes, the
G:C.T:A change was still the most common type of
mutation. The x-axis denotes the number of SNV mutations,
and the y-axis lists the mutation types (see supplementary
Fig. 2).
3) InDel. We used paired-end reads for gap alignment using
SAMtoolsmpileup software to detect InDels and ANNOVAR to
annotate and classify them. A statistical analysis of InDel
distribution (see supplementary Table 3) was generated in
order to evaluate the number of InDels in different gene
regions.
To identify the somatic InDels, those also present in normal
samples were filtered out. Hence, we used a program
developed in-house to filter the *.vcf files which included the
InDel information for normal and tumor samples. A statistical
analysis of somatic InDel distribution was generated in order
to evaluate the number of InDels in different gene regions.
4) CNV. Differences in CNVs between the normal and tumor
genomes (see supplementary Table 4) were detected by
software developed in-house using an algorithm similar to
Segseq developed by the Broad institute. After identifying the
CNVs, we used ANNOVAR to annotate and classify them. A
statistical analysis of CNV distribution was generated in order
to evaluate the number of CNV located in different gene
regions.
Identification of Acquired Gene Aberrations during
Imatinib Treatment
In order to identify new mutations upon the emergence of
imatinib resistance, we compared the whole genome of the pre-
and post-treatment biopsy specimens. Among a total of 46 somatic
mutations identified, 22 somatic mutations overlapped between
the pre- and post-treatment tumor tissue and 12 somatic mutations
were identified only in the pre-treatment tumor tissue (Fig. 3).
There were 12 somatic mutations identified only in the post-
treatment tumor tissue in which imatinib resistance had
developed. Among them, as shown in Table 1, eight non-
synonymous mutations were observed in the following genes:
ACAP2, CARD10, KIAA0556, PAQR7, PPP1R39, SAFB2, STARD9,
and ZFYVE9. No significant copy number alterations, insertion,
and deletions were idenfied during imatinib treatment as shown in
supplementary material.
Discussion
Using whole-genome sequencing of both pre-treatment and
post-treatment tumor tissues, we identified eight non-synonymous
and one stop-gain mutations in eight genes that emerged at the
same time that the tumor became resistant to imatinib. The
accuracy of our 506 sequencing depth and mutation calling
method has been validated in another dataset (data not shown)
with 82.2% of sensitivity and more than 95% of specificity. This
allowed us to identify potential drug resistance mechanisms in this
DFSP patient who initially responded well to imatinib but suffered
rapidly progressive disease 6 months after treatment. DFSP is a
very rare soft tissue sarcoma, and misdiagnosis, multiple equivocal
biopsies, and/or a delay in accurate diagnosis are common in the
clinical history of the patients with this disease [21]. For a more
accurate diagnosis of DFSP, the National Comprehensive Cancer
Network guidelines recommend hematoxylin and eosin staining
along with immunostaining for markers such as CD34, factor
XIIIa, tenascin, and/or stromelysin-3 [22–24]. The guidelines do
not however recommend re-biopsy when the diagnosis of DFSP is
clinically suspicious but not supported by initial pathology [21].
Surgical resection is the standard management approach for
localized disease [4,5], but systemic treatment with imatinib is the
standard first-line treatment for inoperable and metastatic DFSP
[17,18,21].
Imatinib mesylate (imatinib) is an orally active small-molecule
tyrosine kinase inhibitor (TKI) of the breakpoint cluster region-
Abelson murine leukemia (BCR-ABL) fusion protein, KIT,
platelet-derived growth factor receptor a (PDGFRA), and
platelet-derived growth factor receptor b (PDGFRB). Imatinib
has revolutionized the treatment of certain malignancies and has
become a paradigm for molecular targeted therapy. It has
fundamentally changed the way in which chronic myeloid
leukemia (CML) is treated, as BCR-ABL is a major driver of this
malignancy [25–27]. It also shows very high efficacy in the
treatment of gastrointestinal stromal tumor (GIST) through
targeting KIT and PDGFRA, which have critical roles in
oncogenic signaling [28,29]. Preclinical studies of DFSP showed
that the constitutive activation of the PDGFRB tyrosine kinase
Figure 2. Pathological examination of tumor. A, Hematoxylin-eosin staining is showing spindle-shaped cells organized in a storiform pattern
characteristic of DFSP (6100 magnification). B, (6200 magnification).
doi:10.1371/journal.pone.0069752.g002
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domain resulting from t(17;22)(q22;q13) translocation together
with COL1A1-PDGFB gene rearrangement was essential for DFSP
pathogenesis [11], suggesting that DFSP could be targeted by
imatinib. Subsequently, a number of case reports and a recent
pooled analysis of 2 phase II trials (SWOG-S0345 and EORTC
62027) have also reported promising efficacy of imatinib for
advanced and metastatic DFSP [13,14,17,18].
Despite this apparent success with imatinib, drug resistance
eventually occurs in most CML and GIST cases [30–32]. In CML,
this can result from further point mutations leading to additional
changes in BCR-ABL, for example T315I, Y253H, and F255K
[33]. In GIST, secondary KIT mutations in exons 13, 14, or 17
other than exon 11 are reported to be important events in
acquired imatinib resistance [34]. When viewed in terms of tumor
heterogeneity and clonal evolution, selective therapeutic pressure
exerted by imatinib can lead to the elimination of imatinib-
sensitive clones and the subsequent expansion of imatinib-resistant
clones. As a result, the identification of imatinib resistance
mechanisms in CML and GIST could lead to the development
of effective second- or third-line treatment strategies, such as
imatinib dose escalation and second-generation TKIs including
dasatinib and nilotinib for CML [35–37] and sunitinib for GIST
[38].
Despite these advances, the mechanisms of resistance to
PDGFRB inhibition by imatinib and effective second-line
treatment strategies for DFSP have not been identified, and
DFSP patients who fail imatinib treatment have no further
rationale-based treatment options. Recently, next-generation
sequencing has enabled us to identify recurrent mutations
associated with cancer pathogenesis and to define clonal evolution
patterns in diverse malignancies [39–44]. Moreover, by comparing
mutational changes in the pre-treatment and post-treatment
cancer specimens using whole-genome sequencing, important
advances in the determination of acquired drug resistance
mechanisms to the BRAF inhibitor vemurafenib have been made
in malignant melanoma [45,46].
In this study, we investigated the changes in the mutational
spectrum before and after imatinib treatment by whole-genome
sequencing and tried to identify the mutational events associated
with imatinib resistance in DFSP. The COL1A1-PDGFB fusion
gene was detected in both imatinib-resistant and imatinib-sensitive
tumors and COL1A1-PDGFB rearrangement was reconfirmed by
PCR, but no point mutation or copy number change was detected
in the PDGFB gene of the imatinib-resistant tumor. Moreover,
most CNVs overlapped between imatinib-resistant and imatinib-
sensitive tumors (supplementary material). Taken together, these
findings suggest that, although the COL1A1-PDGFB fusion gene
may have been involved in the original pathogenesis of DFSP, it
was not involved the subsequent acquisition of imatinib resistance.
Table 1 summarizes eight newly identified mutations in the
imatinib-resistant tumor tissue of this DFSP patient, which were
not detectable in the imatinib-sensitive tumor. This finding
includes mutations in the CARD10, PPP1R39, SAFB2, and
STARD9 genes. CARD10 is associated with the activation of the
NK-kB signaling pathway and is known to have clinical
implications in gastric cancer, colon cancer, and non-small cell
lung cancer [47–51]. A potential role for changes in the PPP1R39
gene has also been suggested in the development of human cancers
[52]. Further, the SAFB2 gene product is involved in a variety of
cellular process, such as cell growth, apoptosis, and stress response
Figure 3. Sequencing data analysis. The value of x-axis denotes the allelle frequency of imatinib-sensitive tumor sample and the value of y-axis
denotes the allelle frequency of imatinib-resistant tumor sample of the respective 46 somatic mutations.
doi:10.1371/journal.pone.0069752.g003
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and is associated with breast tumorigenesis [53–55]. In a recent in
vitro study, the STARD9 gene product was shown to be associated
with mitotic microtubule formation and cell division and might be
a potential candidate target to extend the reach of cancer
therapeutics [56]. Among the studies mentioned above, Crone et
al. demonstrated that targeting CARD10 by microRNA-146a
inhibited NF-kB signaling pathway activation in gastric cancer cell
lines via reduction of tumor-promoting cytokines and growth
factors including PDGFRB [49]. This study showed the possible
association between CARD10 inhibition and decreased level of
PDGFR and also implied CARD10 activating mutation may be
one of the possible resistance mechanism to PBGFR inhibition by
imatinib in DFSP.
We initially undertook this study to identify newly emerged
somatic mutations that could help identify salvage treatment
strategies specific for this patient. However, despite identifying
eight non-synonymous somatic mutations in the imatinib-resistant
tumor, there were no drugs or functional studies available for the
candidate genes. We plan to prospectively procure more imatinib-
resistant specimens of this rare tumor type, which has limited
treatment options after the failure of imatinib treatment.
Conclusions
This study revealed diverse possible candidate mechanisms by
which imatinib resistance to PDGFRB inhibition may arise, and
suggests the need for further studies for validating ACAP2,
CARD10, KIAA0556, PAAQR7, PPP1R39, SAFB2, STARD9, and
ZFYVE9 as candidate genes involved in imatinib resistance. The
results also highlight the utility of whole-genome sequencing in
identifying drug resistance mechanisms and the possibility of
genome-directed, personalized anti-cancer therapy based on
whole-genome sequencing technology.
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Y axis is the total SNV number in each mutation type category).
Figure S1a. (a) Illustration of mutation spectrum for SNV in
imatinib sensitive DFSP. Figure S1b. (b) Illustration of mutation
spectrum for SNV in imatinib resistant DFSP.
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